CTLA4 and cancer: Immunotherapies targeting immune checkpoint receptors or ligands such as Cytotoxic T-Lymphocyte-Associated protein-4 (CTLA-4), Programmed Death -1 (PD-1) and its ligand (PD-L1), are currently being widely exploited in clinical trials for multiple cancer types.